Pneumolysin as a potential therapeutic target in severe pneumococcal disease

Journal of Infection

Volumn 74, Issue 6, 2017, Pages 527-544

  Anderson, Ronald ^a   Feldman, Charles ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

Aspirin; Corticosteroids; Macrolides; Pneumococcus; Protease activated receptor 1; Statins; Streptococcus pneumoniae; Vorapaxar

Indexed keywords

ACETYLSALICYLIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFTRIAXONE; CLARITHROMYCIN; CORTICOSTEROID; CRYOPYRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MACROLIDE; MANNAN BINDING LECTIN; MYELOID DIFFERENTIATION FACTOR 88; PNEUMOLYSIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIMVASTATIN; SOLITHROMYCIN; TETRACYCLINE DERIVATIVE; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; ANTITHROMBOCYTIC AGENT; BACTERIAL PROTEIN; LACTONE; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; PYRIDINE DERIVATIVE; STREPTOLYSIN; VORAPAXAR;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; HOST RESISTANCE; HUMAN; INFECTION RISK; NONHUMAN; PATHOGENESIS; PNEUMOCOCCAL INFECTION; RESPIRATORY FAILURE; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE ACTIVATION; ADJUVANT CHEMOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COMPLICATION; INFLAMMATION; LUNG; METABOLISM; MICROBIOLOGY; MOUSE; PATHOGENICITY; PATHOLOGY; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE;

ADRENAL CORTEX HORMONES; ANIMALS; BACTERIAL PROTEINS; CHEMOTHERAPY, ADJUVANT; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LACTONES; LUNG; MACROLIDES; MICE; PLATELET AGGREGATION INHIBITORS; PNEUMOCOCCAL INFECTIONS; PNEUMONIA, PNEUMOCOCCAL; PYRIDINES; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

EID: 85016002502     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2017.03.005     Document Type: Review

References (189)

1. 1 Isturiz, R.E., Luna, C.M., Ramirez, J., Clinical and economic burden of pneumonia among adults in Latin America. Int J Infect Dis 14 (2010), e852–e856.
2. 2 File, T.M. Jr., Marrie, T.J., Burden of community-acquired pneumonia in North American adults. Postgrad Med 122 (2010), 130–141.
3. 3 Song, J.H., Thamlikitkul, V., Hsueh, P.R., Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents 38 (2011), 108–117.
4. 4 Welte, T., Torres, A., Nathwani, D., Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67 (2012), 71–79.
5. 5 Sanz Herrero, F., Blanguer Olivas, J., Microbiology and risk factors for community-acquired pneumonia. Semin Respir Crit Care Med 33 (2012), 220–231.
6. 6 Drijkoningen, J.J., Rohde, G.G.U., Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 20 (2014), 45–51.
7. 7 Scott, J.A., The preventable burden of pneumococcal disease in the developing world. Vaccine 25 (2007), 2398–2405.
8. 8 Ludwig, E., Bonanni, P., Rohde, G., Sayiner, A., Torres, A., The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 21 (2012), 57–65.
9. 9 Said, M.A., Johnson, H.L., Nonyane, B.A., Deloria-Knoll, M., O'Brien, K.L., AGEDD Adult Pneumococcal Burden Study Team, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One, 8, 2013, e60273.
10. 10 Chalmers, J.D., Campling, J., Dicker, A., Woodhead, M., Madhava, H., A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med, 16, 2016, 77.
11. 11 Torres, A., Peetermans, W.E., Viegi, G., Blasi, F., Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax 68 (2013), 1057–1065.
12. 12 McCullers, J.A., The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 12 (2014), 252–262.
13. 13 Torres, A., Blasi, F., Dartois, N., Akova, M., Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 70 (2015), 984–989.
14. 14 Curcio, D., Cané, A., Isturiz, R., Redefining risk categories for pneumococcal disease in adults: critical analysis of the evidence. Int J Infect Dis 37 (2015), 30–35.
15. 15 Feldman, C., Anderson, R., Epidemiology, virulence factors and management of the pneumococcus. F1000Res, 5, 2016, 2320.
16. 16 Ram, S., Lewis, L.A., Rice, P.A., Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 23 (2010), 740–780.
17. 17 Chidiac, C., Pneumococcal infections and adult with risk factors. Med Mal Infect 42 (2012), 517–524.
18. 18 Sinwar, P.D., Overwhelming post splenectomy infection syndrome – review study. Int J Surg 12 (2014), 1314–1316.
19. 19 Theilacker, C., Ludewig, K., Serr, A., Schimpf, J., Held, J., Bögelein, M., et al. Overwhelming postsplenectomy infection: a prospective multicenter cohort study. Clin Infect Dis 62 (2016), 871–878.
20. 20 Martinot, M., Oswald, L., Parisi, E., Etienne, E., Argy, N., Grawey, I., et al. Immunoglobulin deficiency in patients with Streptococcus pneumoniae or Haemophilus influenzae invasive infections. Int J Infect Dis 79 (2014), 79–84.
21. 21 Picard, C., Casanova, J.L., Puel, A., Infectious diseases in patients with IRAK-4, MyD88, NEMO, or IκBα deficiency. Clin Microbiol Rev 24 (2011), 490–497.
22. 22 Von Bernuth, H., Picard, C., Puel, A., Casanova, J.L., Experimental and natural infections in MyD88- and IRAK-4-deficient mice and humans. Eur J Immunol 42 (2012), 3126–3135.
23. 23 Calbo, E., Garau, J., Factors affecting the development of systemic inflammatory response syndrome in pneumococcal infections. Curr Opin Infect Dis 24 (2011), 241–247.
24. 24 Vernatter, J., Pirofski, L.A., Current concepts in host-microbe interaction leading to pneumococcal pneumonia. Curr Opin Infect Dis 26 (2013), 277–283.
25. 25 Henriques-Normark, B., Tuomanen, E.I., The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med, 3, 2013, 010215.
26. 26 Donkor, E.S., Badoe, E.V., Insights into pneumococcal pathogenesis and antibiotic resistance. Adv Microbiol 4 (2014), 627–643, 10.4236/aim.2014.410069.
27. 27 Wootton, D.G., Aston, S.J., Gordon, S.B., The pathophysiology of pneumococcal pneumonia. Chalmers, J.D., Pletz, M.W., Aliberti, S., (eds.) Community-acquired pneumonia European Respiratory Society. Eur Respir Monogr, vol. 63, 2014, 42–63, 10.1183/1025448x.10003313.
28. 28 Song, J.Y., Nahm, M.H., Moseley, M.A., Clinical implications of pneumococcal serotypes: invasive disease potential, clinical presentations, and antibiotic resistance. J Korean Med Sci 28 (2013), 4–15.
29. 29 Ritchie, N.D., Mitchell, T.J., Evans, T.J., What is different about serotype 1 pneumococci?. Future Microbiol 7 (2012), 33–46.
30. 30 Luján, M., Gallego, M., Rello, J., Optimal therapy for severe pneumococcal community-acquired pneumonia. Intensive Care Med 32 (2006), 971–980.
31. 31 Grabenstein, J.D., Musey, L.K., Differences in serious clinical outcomes of infection caused by specific pneumococcal serotypes among adults. Vaccine 32 (2014), 2399–2405.
32. 32 Harboe, Z.B., Thomsen, R.W., Riis, A., Valentiner-Branth, P., Christensen, J.J., Lambertsen, L., et al. Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med, 6, 2009, e1000081.
33. 33 Jansen, A.G., Rodenburg, G.D., van der Ende, A., van Alphen, L., Veenhoven, R.H., Spanjaard, L., et al. Invasive pneumococcal disease among adults: associations among serotypes, disease characteristics, and outcome. Clin Infect Dis 49 (2009), e23–e29.
34. 34 Weinberger, D.M., Harboe, Z.B., Sanders, E.A., Ndiritu, M., Klugman, K.P., Rückinger, S., et al. Association of serotype with risk of death due to pneumococcal pneumonia: a meta-analysis. Clin Infect Dis 51 (2010), 692–699.
35. 35 Garcia-Vidal, C., Ardanuy, C., Tubau, F., Viasus, D., Dorca, J., Liñares, J., et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax 65 (2010), 77–81.
36. 36 Ahl, J., Littorin, N., Forsgren, A., Odenholt, I., Resman, F., Riesback, K., High incidence of septic shock caused by Streptococcus pneumoniae serotype 3 – a retrospective epidemiological study. BMC Infect Dis, 13, 2013, 492.
37. 37 Burgos, J., Luján, M., Larrosa, M.N., Fontanals, D., Burmudo, G., Planes, A.M., et al. Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J 43 (2014), 545–553.
38. 38 Fruchtman, S.M., Gombert, M.E., Lyons, H.A., Adult respiratory distress syndrome as a cause of death in pneumococcal pneumonia. Report of ten cases. Chest 83 (1983), 598–601.
39. 39 Witzenrath, M., Gutbier, B., Hocke, A.C., Schmerck, B., Hippenstiel, S., Berger, K., et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med 34 (2006), 1947–1954.
40. 40 Rubins, J.B., Duane, P.G., Clawson, D., Charboneau, D., Young, J., Niewoehner, D.E., Toxicity of pneumolysin to pulmonary alveolar epithelial cells. Infect Immun 61 (1993), 1352–1358.
41. 41 Witzenrath, M., Gutbier, B., Owen, J.S., Schmeck, B., Mitchell, T.J., Mayer, K., et al. Role of platelet-activating factor in pneumolysin-induced acute lung injury. Crit Care Med 35 (2007), 1756–1762.
42. 42 Musher, D.M., Rueda, A.M., Kaka, A.S., Mapara, S.M., The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 45 (2007), 158–165.
43. 43 Brown, A.O., Mann, B., Gao, G., Hankins, J.S., Humann, J., Giardina, J., et al. Steptococcus pnemoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog, 10, 2014, e1004383.
44. 44 Alhamdi, Y., Neill, D.R., Abrams, S.T., Malak, H.A., Yahya, R., Barrett-Jolley, R., et al. Circulating pneumolysin is a potent inducer of cardiac injury during pneumococcal infection. PLoS Pathog, 11, 2015, e1004836.
45. 45 Brown, A.O., Millett, E.R., Quint, J.K., Orihuela, C.J., Cardiotoxicity during invasive pneumococcal disease. Am J Respir Crit Care Med 191 (2015), 739–745.
46. 46 Mandell, L.A., Wunderink, R.G., Anzueto, A., Barlett, J.G., Campbell, G.D., Dean, N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 (2007), S27–S72.
47. 47 Woodhead, M., Blasi, F., Ewig, S., Garau, J., Huchon, G., Ieven, M., et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin Microbiol Infect 17 (2011), E1–E59.
48. 48 Lim, W.S., Smith, D.L., Wise, M.P., Welham, S.A., British Thoracic Society. British Thoracic Society community-acquired pneumonia guideline and the NICE pneumonia guideline: how they fit together. Thorax 70 (2015), 698–700.
49. 49 Baddour, L.M., Yu, V.L., Klugman, K.P., Feldman, C., Ortqvist, A., Rello, J., et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 170 (2004), 440–444.
50. 50 Lodise, T.P., Kwa, A., Cosler, L., Gupta, R., Smith, R.P., Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother 51 (2007), 3977–3982.
51. 51 Sligl, W.I., Asadi, L., Eurich, D.T., Tjosvold, L., Marrie, T.J., Majumdar, S.R., Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis. Crit Care Med 42 (2014), 420–432.
52. 52 Gattarello, S., Borgatta, B., Solé-Violán, J., Vallés, J., Vidaur, L., Zaragoza, R., et al. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000–2013). Chest 146 (2014), 22–31.
53. 53 Gattarello, S., What is new in antibiotic therapy in community-acquired pneumonia? An evidence-based approach focusing on combined therapy. Curr Infect Dis Rep, 17, 2015, 501.
54. 54 Feldman, C., Anderson, R., Therapy for pneumococcal bacteremia: monotherapy or combination therapy?. Curr Opin Infect Dis 22 (2009), 137–142.
55. 55 Berjohn, C.M., Fishman, N.O., Joffe, M.M., Edelstein, P.H., Metlay, J.P., Treatment and outcomes for patients with bacteremic pneumococcal pneumonia. Medicine 87 (2008), 160–166.
56. 56 Mongardon, N., Max, A., Bouglé, A., Pène, F., Lemiale, V., Charpentier, J., et al. Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive care unit: a multicenter study. Crit Care, 16, 2012, R155.
57. 57 GBD 2013 Mortality and Causes of Death Collaborators, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385 (2015), 117–171.
58. 58 Wunderink, R.G., Mandell, L., Adjunctive therapy in community-acquired pneumonia. Semin Respir Crit Care Med 33 (2012), 311–318.
59. 59 Faverio, P., Restrepo, M.I., Non-antibiotic therapies for CAP. Chalmers, J.D., Pletz, M.W., Aliberti, S., (eds.) Community-acquired pneumonia European Respiratory Society. Eur Respir Monogr, vol. 63, 2014, 219–233, 10.1183/1025448x.10004513.
60. 60 Lucas, R., Czikora, I., Sridhar, S., Zemskov, E., Gorshkov, B., Sidderamappa, U., et al. Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs. Toxins 5 (2013), 1244–1260.
61. 61 Mitchell, T.J., Dalziel, C.E., The biology of pneumolysin. Subcell Biochem 80 (2014), 145–160.
62. 62 Geno, K.A., Gilbert, G.L., Song, J.Y., Skovsted, I.C., Klugman, K.P., Jones, C., et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev 28 (2015), 871–899.
63. 63 Kirkham, L.S., Jefferies, J.M., Kerr, A.R., Jing, Y., Clarke, S.C., Smith, A., et al. Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin. J Clin Microbiol 44 (2006), 151–159.
64. 64 Jefferies, J.M., Johnston, C.H., Kirkham, L.S., Cowan, G.J., Ross, K.S., Smith, A., et al. Presence of nonhemolytic pneumolysin in serotypes of Streptococcus pneumoniae associated with disease outbreaks. J Infect Dis 196 (2007), 936–944.
65. 65 Price, K.E., Camilli, A., Pneumolysin localizes to the cell wall of Streptococcus pneumonia. J Bacteriol 191 (2009), 2163–2168.
66. 66 Farrand, A.J., LaChapelle, S., Hotze, E.M., Johnson, A.E., Tweten, R.K., Only two amino acids are essential for cytolytic toxin recognition of cholesterol at the membrane surface. Proc Natl Acad Sci USA 107 (2010), 4341–4346.
67. 67 Bokori-Brown, M., Petrov, P.G., Khafaji, M.A., Mughal, M.K., Naylor, C.E., Shore, A.C., et al. Red blood cell susceptibility to pneumolysin: correlation with membrane biochemical and physical properties. J Biol Chem 291 (2016), 10210–10227.
68. 68 Gilbert, R.J., Sonnen, A.F., Measuring kinetic drivers of pneumolysin pore structure. Eur Biophys J 45 (2016), 365–376.
69. 2+-dependent repair of pneumolysin pores: a new paradigm for host cellular defense against bacterial pore-forming toxins. Biochim Biophys Acta 1853 (2015), 2045–2054.
70. 70 Wolfmeier, H., Radecke, J., Schoenauer, R., Koeffel, R., Babiychuk, V.S., Drücker, P., et al. Active release of pneumolysin prepores and pores by mammalian cells undergoing a Streptococcus pneumoniae attack. Biochim Biophys Acta 1860 (2016), 2498–2509.
71. 71 Clark, R.A., Oxidative inactivation of pneumolysin by the myeloperoxidase system and stimulated human neutrophils. J Immunol 136 (1986), 4617–4622.
72. 72 Ali, Y.M., Kenawy, H.I., Muhammad, A., Sim, R.B., Andrew, P.W., Schwaeble, W.J., Human L-ficolin, a recognition molecule of the lectin activation pathway of complement, activates complement by binding to pneumolysin, the major toxin of Streptococcus pneumoniae. PLoS One, 8, 2013, e82583.
73. 73 Feldman, C., Anderson, R., The role of Streptococcus pneumoniae in community-acquired pneumonia. Semin Respir Crit Care Med 37 (2016), 806–818, 10.1055/s-0036-1592074.
74. 74 Zafar, M.A., Wang, Y., Hamaguchi, S., Weiser, J.N., Host-to-host transmission of Streptococcus pneumoniae is driven by its inflammatory toxin, pneumolysin. Cell Host Microbe 21 (2017), 73–83.
75. 75 Nelson, A.L., Roche, A.M., Gould, J.M., Chim, K., Ratner, A.J., Weiser, J.N., Capsule enhances pneumococcal colonization by limiting mucus-mediated clearance. Infect Immun 75 (2007), 83–90.
76. 76 Feldman, C., Mitchell, T.J., Andrew, P.W., Boulnois, G.J., Read, R.C., Todd, H.C., et al. The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro. Microb Pathog 9 (1990), 275–284.
77. 77 Hotomi, M., Yuasa, J., Briles, D.E., Yamanaka, N., Pneumolysin plays a key role at the initial step of establishing pneumococcal nasal colonization. Folia Microbiol 61 (2016), 375–383.
78. 78 Hermand, P., Vandercammen, A., Mertens, E., Di Paolo, E., Verlant, V., Denoël, P., et al. Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen. Hum Vaccin Immunother 13 (2017), 220–228.
79. 79 Zhang, Z., Clarke, T.B., Weiser, J.N., Cellular effectors mediating Th17-dependent clearance of pneumococcal colonization in mice. J Clin Invest 119 (2009), 1899–1909.
80. 80 Bergmann, S., Lang, A., Rohde, M., Agarwal, V., Rennemeier, C., Grashoff, C., et al. Integrin-linked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells. J Cell Sci 122 (2009), 256–267.
81. 81 Thornton, R.B., Rigby, P.J., Wiertsema, S.P., Filion, P., Langlands, J., Coates, H.L., et al. Multi-species bacterial biofilm and intracellular infection in otitis media. BMC Pediatr, 11, 2011, 94.
82. 82 Marks, L.R., Parameswaran, G.I., Hakansson, A.P., Pneumococcal interactions with epithelial cells are crucial for optimal biofilm formation and colonization in vitro and in vivo. Infect Immun 80 (2012), 2744–2760.
83. 83 McCullers, J.A., Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 19 (2006), 571–582.
84. 84 Jones, C.V., Williams, T.M., Walker, K.A., Dickinson, H., Sakkal, S., Rumballe, B.A., et al. M2 macrophage polarisation is associated with alveolar formation during postnatal lung development. Respir Res, 14, 2013, 41.
85. 85 Yang, Y., Wu, B.Q., Wang, Y.H., Shi, Y.F., Luo, J.M., Ba, J.H., et al. Regulatory effects of miR-155 and miR-146a on repolarization and inflammatory cytokine secretion in human alveolar macrophages in vitro. Immunopharmacol Immunotoxicol, 2016, 10.1080/08923973.2016.1248845 [Epub ahead of print].
86. 86 González-Juarbe, N., Gilley, R.P., Hinojosa, C.A., Bradley, K.M., Kamei, A., Gao, G., et al. Pore-forming toxins induce macrophage necroptosis during acute bacterial pneumonia. PLoS Pathog, 11, 2015, e1005337.
87. 87 Kitur, K., Parker, D., Nieto, P., Ahn, D.S., Cohen, T.S., Chung, S., et al. Toxin-induced necroptosis is a major mechanism of Staphylococcus aureus lung damage. PLoS Pathog, 11, 2015, e1004820.
88. 88 Gilley, R.P., González-Juarbe, N., Shenoy, A.T., Reyes, L.F., Dube, P.H., Restrepo, M.I., et al. Infiltrated macrophages die of pneumolysin-mediated necroptosis following pneumococcal myocardial invasion. Infect Immun 84 (2016), 1457–1469.
89. 89 Aberdein, J.D., Cole, J., Bewley, M.A., Marriott, H.M., Dockrell, D.H., Alveolar macrophages in pulmonary host defence the unrecognized role of apoptosis as a mechanism of intracellular bacterial killing. Clin Exp Immunol 174 (2013), 193–202.
90. 90 Bewley, M.A., Naughton, M., Preston, J., Mitchell, A., Holmes, A., Marriott, H.M., et al. Pneumolysin activates macrophage lysosomal membrane permeabilization and executes apoptosis by distinct mechanisms without membrane pore formation. MBio, 5, 2014 e01710–14.
91. 91 Chen, X., Li, W., Ren, J., Huang, D., He, W.T., Song, Y., et al. Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death. Cell Res 24 (2014), 105–121.
92. 92 Lemon, J.K., Weiser, J.N., Degradation products of the extracellular pathogen Streptotoccus pneumoniae access the cytosol via its pore-forming toxin. MBio, 6, 2015, e02110.
93. + efflux. J Immunol 194 (2015), 1763–1775.
94. 94 Hassane, M., Demon, D., Soulard, D., Fontaine, J., Keller, L.E., Patin, E.C., et al. Neutrophilic NLRP3 inflammasome-dependent IL-1β secretion regulates the γδT17 cell response in respiratory bacterial infections. Mucosal Immunol, 2017, 10.1038/mi.2016.113 [Epub ahead of print].
95. 95 García-Suárez Mdel, M., Flórez, N., Astudillo, A., Vázquez, F., Villaverde, R., Fabrizio, K., et al. The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model. Respir Res, 8, 2007, 3.
96. 96 Ohkuni, H., Nagamune, H., Ozaki, N., Tabata, A., Todome, Y., Watanabe, Y., et al. Characterization of recombinant Streptococcus mitis-derived human platelet aggregation factor. APMIS 120 (2012), 56–71.
97. 97 Nel, J.G., Durandt, C., Mitchell, T.J., Feldman, C., Anderson, R., Tintinger, G.R., Pneumolysin mediates platelet activation in vitro. Lung 194 (2016), 589–593.
98. 98 Nel, J.G., Durandt, C., Theron, A.J., Tintinger, G.R., Pool, R., Richards, G.A., et al. Pneumolysin mediates heterotypic aggregation of neutrophils and platelets in vitro. J Infect 74 (2017), 599–608.
99. 99 Bonten, M.J., Huijts, S.M., Bolkenbaas, M., Webber, C., Patterson, S., Gault, S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372 (2015), 1114–1125.
100. 100 Bruce, M.G., Singleton, R., Bulkow, L., Rudolph, K., Zulz, T., Gounder, P., et al. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska. Vaccine 33 (2015), 4813–4819.
101. 101 Nair, H., Watts, A.T., Williams, L.J., Omer, S.B., Simpson, C.R., Willocks, L.J., et al. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children. BMC Infect Dis, 16, 2016, 390.
102. 102 Feldman, C., Anderson, R., Community-acquired pneumonia: still a major burden of disease. Curr Opin Crit Care 22 (2016), 477–484.
103. 103 García-Suárez Mdel, M., Cima-Cabal, M.D., Flórez, N., García, P., Cernuda-Cernuda, R., Astudillo, A., et al. Protection against pneumococcal pneumonia in mice by monoclonal antibodies to pneumolysin. Infect Immun 72 (2004), 4534–4540.
104. 104 Cockeran, R., Anderson, R., Feldman, C., Pneumolysin as a vaccine and drug target in the prevention and treatment of invasive pneumococcal disease. Arch Immunol Ther Exp 53 (2005), 189–198.
105. 105 Li, H., Zhao, X., Wang, J., Dong, Y., Meng, S., Li, R., et al. β-Sitosterol interacts with pneumolysin to prevent Streptococcus pneumoniae infection. Sci Rep, 5, 2015, 17668.
106. 106 Henry, B.D., Neill, D.R., Becker, K.A., Gore, S., Bricio-Moreno, L., Ziobro, R., et al. Engineered liposomes sequester bacterial exotoxins and protect from severe invasive infections in mice. Nat Biotechnol 33 (2015), 81–88.
107. 107 Zhao, X., Li, H., Wang, J., Guo, Y., Liu, B., Deng, X., et al. Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin oligomers. Mol Pharmacol 89 (2016), 376–387.
108. 108 Song, M., Li, L., Li, M., Cha, Y., Deng, X., Wang, J., Apigenin protects mice from pneumococcal pneumonia by inhibiting the cytolytic activity of pneumolysin. Fitoterapia 115 (2016), 31–36, 10.1016/j.fitote.2016.09.017.
109. 109 Zhao, X., Liu, B., Liu, S., Wang, L., Wang, J., Anticytotoxin effects of amentoflavone to pneumolysin. Biol Pharm Bull 40 (2017), 61–67.
110. 110 Spoorenberg, S.M., Bos, W.J., Heijligenberg, R., Voorn, P.G., Grutters, J.C., Rijkers, G.T., et al. Microbial aetiology, outcomes, and costs of hospitalisation for community-acquired pneumonia; an observational analysis. BMC Infect Dis, 14, 2014, 335.
111. 111 Jain, S., Self, W.H., Wunderink, R.G., Fakhran, S., Balk, R., Bramley, A.M., et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373 (2015), 415–427.
112. 112 Martin-Loeches, I., Lisboa, T., Rodriguez, A., Putensen, C., Annane, D., Garnacho-Montero, J., et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36 (2010), 612–620.
113. 113 Bender, M.T., Niederman, M.S., Improving outcomes in community-acquired pneumonia. Curr Opin Pulm Med 22 (2016), 235–242.
114. 114 Emmet O'Brien, M., Restrepo, M.I., Martin-Loeches, I., Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. Respir Investig 53 (2015), 201–209.
115. 115 Horita, N., Otsuka, T., Haranaga, S., Namkoong, H., Miki, M., Miyashita, N., et al. Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis. Respirology 21 (2016), 1193–1200.
116. 116 Shorr, A.F., Zilberberg, M.D., Kan, J., Hoffman, J., Micek, S.T., Kollef, M.H., Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study. BMJ Open, 3, 2013, e002898.
117. 117 Anderson, R., Tintinger, G., Cockeran, R., Potjo, M., Feldman, C., Beneficial and harmful interactions of antibiotics with microbial pathogens and the host innate immune system. Pharmaceuticals 3 (2010), 1694–1710, 10.3390/ph3051694.
118. 118 Steel, H.C., Theron, A.J., Cockeran, R., Anderson, R., Feldman, C., Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics. Mediators Inflamm, 2012, 2012, 584262.
119. 119 Lagrou, K., Peetermans, W.E., Jorissen, M., Verhaegen, J., Van Damme, J., Van Eldere, J., Subinhibitory concentrations of erythromycin reduce pneumococcal adherence to respiratory epithelial cells in vitro. J Antimicrob Chemother 46 (2000), 717–723.
120. 120 Spreer, A., Kerstan, H., Böttcher, T., Gerber, J., Siemer, A., Zysk, G., et al. Reduced release of pneumolysin by Streptococcus pneumoniae in vitro and in vivo after treatment with nonbacteriolytic antibiotics in comparison to ceftriaxone. Antimicrob Agents Chemother 47 (2003), 2649–2654.
121. 121 Anderson, R., Steel, H.C., Cockeran, R., Smith, A.M., von Gottberg, A., de Gouveia, L., et al. Clarithromycin alone and in combination with ceftriaxone inhibits the production of pneumolysin by both macrolide-susceptible and macrolide-resistant strains of Streptococcus pneumoniae. J Antimicrob Chemother 59 (2007), 224–229.
122. 122 Anderson, R., Steel, H.C., Cockeran, R., von Gottberg, A., de Gouveia, L., Klugman, K.P., et al. Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro. J Antimicrob Chemother 60 (2007), 1155–1158.
123. 123 Spreer, A., von Ruden, C., Mitchell, T.J., Eiffert, H., Nau, R., Influence of subinhibitory concentrations of protein-synthesis-inhibiting antibiotics on production and release of the pneumococcal virulence factor pneumolysin in vitro. Chemotherapy 53 (2007), 327–331.
124. 124 Fukuda, Y., Yanagihara, K., Higashiyama, Y., Miyazaki, Y., Hirakata, Y., Mukae, H., et al. Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J 27 (2006), 1020–1025.
125. 125 Yanagihara, K., Izumikawa, K., Higa, F., Tateyama, M., Tokimatsu, I., Hiramatsu, K., et al. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection. Intern Med 48 (2009), 527–535.
126. 126 Kohno, S., Tateda, K., Kadota, J., Fujita, J., Niki, Y., Watanabe, A., et al. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia. J Infect Chemother 20 (2014), 199–207.
127. 127 Zhanel, G.G., Wolter, K.D., Calciu, C., Hogan, P., Low, D.E., Weiss, K., et al. Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data. J Antimicrob Chemother 69 (2014), 2835–2840.
128. 128 Wolter, N., Smith, A.M., Farrell, D.J., Northwood, J.B., Douthwaite, S., Klugman, K.P., Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation. Antimicrob Agents Chemother 52 (2008), 435–440.
129. 129 Cockeran, R., Steel, H.C., Wolter, N., de Gouveia, L., von Gottberg, A., Klugman, K.P., Effects of clarithromycin at sub-minimum inhibitory concentrations on early ermB gene expression, metabolic activity and growth of an erm(B)-expressing macrolide-resistant strain of Streptococcus pneumoniae. Open J Respir Dis 2 (2012), 1–8, 10.4236/ojrd.2012.21001.
130. 130 Zuckerman, J.M., Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin N Am 18 (2004), 621–649.
131. 131 Weisblum, B., Insights into erythromycin action from studies of its activity as inducer of resistance. Antimicrob Agents Chemother 39 (1995), 797–805.
132. 132 Wozniak, D.J., Keyser, R., Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest, 125, 2004 62S–9S.
133. 133 Cilloniz, C., Albert, R.K., Liapikou, A., Gabarrus, A., Rangel, E., Bello, S., et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for Streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med 191 (2015), 1265–1272.
134. 134 Niederman, M.S., Macrolide-resistant pneumococcus in community-acquired pneumonia. Is there still a role for macrolide therapy?. Am J Respir Crit Care Med 191 (2015), 1216–1217.
135. 135 Lin, E., Stanek, R.J., Mufson, M.A., Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 47 (2003), 1151–1153.
136. 136 Yoshioka, D., Kajiwara, C., Ishii, Y., Umeki, K., Hiramatsu, K., Kadota, J., et al. Efficacy of β-lactam-plus-macrolide combination therapy in a mouse model of lethal pneumococcal pneumonia. Antimicrob Agents Chemother 60 (2016), 6146–6154.
137. 137 Van Bambeke, F., Tulkens, P.M., The role of solithromycin in the management of bacterial community-acquired pneumonia. Expert Rev Anti Infect Ther 14 (2016), 311–324.
138. 138 Farrell, D.J., Mendes, R.E., Jones, R.N., Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 59 (2015), 2432–2434.
139. 139 Viasus, D., Ramos, O., Ramos, L., Simonetti, A.F., Carratalà, J., Solithromycin for the treatment of community-acquired bacterial pneumonia. Expert Rev Respir Med 11 (2017), 5–12.
140. 140 Yamamoto, K., Yamamoto, S., Ogasawara, N., Takano, K., Shiraishi, T., Sato, T., et al. Clarithromycin prevents human respiratory syncytial virus-induced airway epithelial responses by modulating activation of interferon regulatory factor-3. Pharmacol Res 111 (2016), 804–814.
141. 141 Harada, T., Ishimatsu, Y., Hara, A., Morita, T., Nakashima, S., Kakugawa, T., et al. Premedication with clarithromycin is effective against secondary bacterial pneumonia during influenza virus infection in a pulmonary emphysema mouse model. J Pharmacol Exp Ther 358 (2016), 457–463.
142. 142 Sun, K., Metzger, D.W., Inhibition of pulmonary antibacterial defense by interferon-gamma during recovery from influenza infection. Nat Med 14 (2008), 558–564.
143. 143 Trinchieri, G., Type I interferon: friend or foe?. J Exp Med 207 (2010), 2053–2063.
144. 144 Lorenzo, M., Moret, I., Sarria, B., Cases, E., Cortijo, J., Méndez, R., et al. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res, 16, 2015, 15.
145. 145 Statt, S., Ruan, J.W., Hung, L.Y., Chang, C.Y., Huang, C.T., Lim, J.H., et al. Statin-conferred enhanced cellular resistance against bacterial pore-forming toxins in airway epithelial cells. Am J Respir Cell Mol Biol 53 (2015), 689–702.
146. 146 Rosch, J.W., Boyd, A.R., Hinojosa, E., Pestina, T., Hu, Y., Persons, D.A., et al. Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 120 (2010), 627–635.
147. 147 Feldman, C., Anderson, R., Community-acquired pneumonia. Pathogenesis of acute cardiac events and potential adjunctive therapies. Chest 148 (2015), 523–532.
148. 148 Viasus, D., Garcia-Vidal, C., Simonetti, A.F., Dorca, J., Llopis, F., Mestre, M., et al. The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. BMJ Open, 5, 2015, e006251.
149. 149 Havers, F., Bramley, A.M., Finelli, L., Reed, C., Self, W.H., Trabue, C., et al. Statin use and hospital length of stay among adults hospitalized with community-acquired pneumonia. Clin Infect Dis 62 (2016), 1471–1478.
150. 150 Wootton, D.G., Diggle, P.J., Court, J., Eneje, O., Keogan, L., Macfarlane, L., et al. Recovery from pneumonia requires efferocytosis which is impaired in smokers and those with low body mass index and enhanced by statins. Thorax 71 (2016), 1052–1054, 10.1136/thoraxjnl-2016-208505.
151. 151 Patel, J., Greenwood, H., Lugg, S., Howells, P., Gao, F., Sapey, E., et al. Simvastatin improves neutrophil migration in elderly patients with septic pneumonia and reduces 6-month mortality and re-admissions: results of the SNOOPI Trial. Thorax, 71(Suppl. 3), 2016, A11, 10.1136/thoraxjnl-2016-209333.22.
152. 152 Grudzinska, F.S., Dancer, R., Thickett, D., Concurrent statin and macrolide use during pneumonia treatment improves survival to hospital discharge and beyond. Thorax, 71(Suppl. 3), 2016, A231, 10.11.3/thoraxjnl-2016-209333.408.
153. 153 Tintinger, G.R., Anderson, R., Feldman, C., Pharmacological approaches to regulate neutrophil activity. Semin Immunopathol 335 (2013), 395–409.
154. 154 Barnes, P.J., Glucocorticosteroids: current and future directions. Br J Pharmacol 163 (2011), 29–43.
155. 155 Hua, G., Ganti, K.P., Chambon, P., Glucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT/NCoR1-HDAC3 repressing complex. Proc Natl Acad Sci USA 113 (2016), E635–E643.
156. 156 Wagner, H.N. Jr., Bennett, I.L. Jr., Lasagna, L., Cluff, L.E., Rosenthal, M.B., Mirick, G.S., The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 98 (1956), 197–215.
157. 157 du Cheyron, D., Lesage, A., Le Page, O., Flais, F., Leclercq, R., Charbonneau, P., Corticosteroids as adjunctive treatment in Austrian's syndrome (pneumococcal endocarditis, meningitis, and pneumonia): report of two cases and review of the literature. J Clin Pathol 56 (2003), 879–881.
158. 158 Lavi, E., Shoseyov, D., Simanovsky, N., Brooks, R., Systemic steroid treatment for severe expanding pneumococcal pneumonia. Case Rep Pediatr, 2015, 2015, 186302.
159. 159 Damjanovic, D., Lai, R., Jeyanathan, M., Hogaboam, C.M., Xing, Z., Marked improvement of severe lung immunopathology by influenza-associated pneumococcal superinfection requires the control of both bacterial replication and host immune responses. Am J Pathol 183 (2013), 868–880.
160. 160 Ghoneim, H.E., McCullers, J.A., Adjunctive corticosteroid therapy improves lung immunopathology and survival during severe secondary pneumococcal pneumonia in mice. J Infect Dis 209 (2014), 1459–1468.
161. 161 Siemieniuk, R.A., Meade, M.O., Alonso-Coello, P., Briel, M., Evaniew, N., Prasad, M., et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163 (2015), 519–528.
162. 162 Tagami, T., Matsui, H., Horiguchi, H., Fushimi, K., Yasunaga, H., Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients. Eur Respir J 45 (2015), 463–472.
163. 163 Feldman, C., Anderson, R., Corticosteroids in the adjunctive therapy of community-acquired pneumonia: an appraisal of recent meta-analyses of clinical trials. J Thorac Dis 8 (2016), E162–E171.
164. 164 Wirz, S.A., Blum, C.A., Schuetz, P., Albrich, W.C., Noppen, C., Mueller, B., et al. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia. Eur Respir J 48 (2016), 1150–1159.
165. 165 Blum, C.A., Nigro, N., Briel, M., Schuetz, P., Ullmer, E., Suter-Widmer, I., et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 385 (2015), 1511–1518.
166. 166 Snijders, D., Daniels, J.M., de Graaff, C.S., van der Werf, T.S., Boersma, W.G., Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med 181 (2010), 975–982.
167. 167 Zhang, S., Wang, J., Chen, S., Yin, J., Pan, Z., Liu, K., et al. Effects of suilysin on Streptococcus suis-induced platelet aggregation. Front Cell Infect Microbiol, 6, 2016, 128.
168. 168 Zhang, S., Zheng, Y., Chen, S., Huang, S., Liu, K., Lv, Q., et al. Suilysin-induced platelet-neutrophil complexes formation is triggered by pore formation-dependent calcium influx. Sci Rep, 6, 2016, 36787.
169. 169 De Stoppelaar, S.F., van ‘t Veer, C., van der Poll, T., The role of platelets in sepsis. Thromb Haemost 112 (2014), 666–677.
170. 170 Claushuis, T.A., van Vught, L.A., Scicluna, B.P., Wiewel, M.A., Klein Klouwenberg, P.M., Hoogendijk, A.J., et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood 127 (2016), 3062–3072.
171. 171 Cangemi, R., Casciaro, M., Rossi, E., Calvieri, C., Bucci, T., Calabrese, C.M., et al. Platelet activation is associated with myocardial infarction in patients with pneumonia. J Am Coll Cardiol 64 (2014), 1917–1925.
172. 172 Cangemi, R., Pignatelli, P., Carnevale, R., Bartimoccia, S., Nocella, C., Falcone, M., et al. Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. J Infect 73 (2016), 107–114.
173. 173 Winning, J., Reichel, J., Eisenhut, Y., Hamacher, J., Kohl, M., Deigner, H.P., et al. Anti-platelet drugs and outcome in severe infection: clinical impact and underlying mechanisms. Platelets 20 (2009), 50–57.
174. 174 Erlich, J.M., Talmor, D.S., Cartin-Ceba, R., Gajic, O., Kor, D.J., Prehospitalization antiplatelet therapy is associated with a reduced incidence of acute lung injury: a population-based cohort study. Chest 139 (2011), 289–295.
175. 175 O'Neal, H.R. Jr., Koyama, T., Koehler, E.A., Siew, E., Curtis, B.R., Fremont, R.D., et al. Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 39 (2011), 1343–1350.
176. 176 Harr, J.N., Moore, E.E., Johnson, J., Chin, T.L., Wohlauer, M.V., Maier, R., et al. Anti-platelet therapy is associated with decreased transfusion-associated risk of lung dysfunction, multiple organ failure, and mortality in trauma patients. Crit Care Med 41 (2013), 399–404.
177. 177 Falcone, M., Russo, A., Cangemi, R., Farcomeni, A., Calvieri, C., Barillà, F., et al. Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc, 4, 2015, e001595.
178. 178 Panka, B.A., de Grooth, H.J., Spoelstra-de Man, A., Looney, M.R., Tuinman, P.R., Prevention or treatment of ARDS with aspirin: a review of preclinical models and meta-analysis of clinical studies. Shock 47 (2016), 13–21, 10.1097/SHK.0000000000000745.
179. 179 Kor, D.J., Erlich, J., Gong, M.N., Malinchoc, M., Carter, R.E., Gajic, O., et al. Association of prehospitalization aspirin therapy and acute lung injury: results of a multicenter international observational study of at-risk patients. Crit Care Med 39 (2011), 2393–2400.
180. 180 Kor, D.J., Carter, R.E., Park, P.K., Festic, E., Banner-Goodspeed, V.M., Hinds, R., et al. Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: the LIPS-A randomized clinical trial. JAMA 315 (2016), 2406–2414.
181. 181 Voiriot, G., Dury, S., Parrot, A., Mayaud, C., Fartoukh, M., Nonsteroidal anti-inflammatory drugs may affect the presentation and course of community-acquired pneumonia. Chest 139 (2011), 387–394.
182. 182 Gibelin, A., de Prost, N., Brun-Buisson, C., Lung abscess complicating pneumococcal pneumonia: a causal role of non-steroidal anti-inflammatory drugs?. BMJ Case Rep, 2013, 200544.
183. 183 Messika, J., Sztrymf, B., Bertrand, F., Billard-Pomares, T., Barnaud, G., Branger, C., et al. Risks of nonsteroidal anti-inflammatory drugs in undiagnosed intensive care unit pneumococcal pneumonia: younger and more severely affected patients. J Crit Care 29 (2014), 733–738.
184. 184 Esposito, A.L., Aspirin impairs antibacterial mechanisms in experimental pneumococcal pneumonia. Am Rev Respir Dis 130 (1984), 857–862.
185. 185 Stables, M.J., Newson, J., Ayoub, S.S., Brown, J., Hyams, C.J., Gilroy, D.W., Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and –resistant bacteria. Blood 116 (2010), 2950–2959.
186. 186 Lee, C.H., Su, L.H., Liu, J.W., Chang, C.C., Chen, R.F., Yang, K.D., Aspirin enhances opsonophagocytosis and is associated to a lower risk for Klebsiella pneumoniae invasive syndrome. BMC Infect Dis, 14, 2014, 47.
187. 4 receptor type 2 protects against pneumolysin-dependent acute lung injury. Sci Rep, 6, 2016, 34560.
188. 188 Pan, H., Boucher, M., Kaunelis, D., PAR-1 antagonists: an emerging antiplatelet drug class. CADTH issues in emerging health technologies, 2016, Canadian Agency for Drugs and Technologies in Health, Ottawa, 148 PMID 27809429.
189. 189 José, R.J., Williams, A.E., Mercer, P.F., Sulikowski, M.G., Brown, J.S., Chambers, R.C., Regulation of neutrophilic inflammation by proteinase-activated receptor 1 during bacterial pulmonary infection. J Immunol 194 (2015), 6024–6034.